Micro Developing Active

McKesson's Target Price Reduction

Gaining traction — growing article coverage and momentum.

Score
0.5
Velocity
▲ 1.0
Articles
3
Sources
2
🤖

AI Overview

McKesson's Stock Price Drops, Target Price Reduced by Evercore ISI

On April 8, McKesson Corp's (MCK) stock price hit an oversold territory, with a Relative Strength Index (RSI) of 27.7, as shares traded as low as $821.99. Meanwhile, Evercore ISI lowered its price target for MCK to $950 from $1,000, while maintaining an 'Outperform' rating. This reduction follows a period of strong net income growth for McKesson, averaging 14.4% over the last three years, with EPS increasing by 19.6% annually.

The pharmaceutical distribution sector and dividend-focused investors are affected. The price target reduction and oversold status of MCK may prompt investors to reassess their positions in the stock, potentially leading to a sell-off. However, the consistent earnings growth may attract value investors seeking undervalued opportunities.

Investors should watch for McKesson's Q3 earnings release on May 6, any updates on the company's strategic initiatives, and further movements in the stock's RSI. These catalysts will provide insights into the stock's valuation and potential recovery.
AI Overview as of Apr 22, 2026

Timeline

Last UpdatedApr 15, 2026